Covid-19 vaccines vs antivirals: Compared to jabs, why are treatments lagging behind in development?

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
0:00
play article
Subscribers can listen to this article
Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial.
Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial.
Plyushkin

Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial. The pill is pending authorisation by the US Food and Drug Administration (FDA) and, if approved, people at high risk of severe Covid-19 would need to take four capsules twice a day for five days at the onset of infection.

To date, the FDA has only fully approved one treatment for Covid-19 – the antiviral remdesivir, which is administered intravenously (via injection) and has been found to shorten recovery time in hospitalised patients, although its effectiveness is debated.

According to the New York Times' treatments and vaccines trackers, 25 other medical treatments for Covid-19 are tentative, compared to 105 vaccines currently being tested in clinical trials.

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism. You can cancel any time.
Subscribe
Already a subscriber? Sign in
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
29% - 9737 votes
No
71% - 23804 votes
Vote